SIOUX FALLS, S.D., Feb. 02, 2024 SAB Biotherapeutics, Inc. , , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte.
By Chris Wack SAB Biotherapeutics said that Samuel J. Reich, currently executive chairman, will expand his role to include that of chief executive, effective.
Form 8-K SAB Biotherapeutics, For: Nov 29 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage company developing a fully-human treatment to delay the progress of type 1 diabetes, said its net loss narrowed in the third quarter. The net loss was $5.1 million, compared to $7.1 million a year earlier, mainly due to cost reduction measures and increased […]